Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » With New Law Passed, NYC Will Consider Testing Options for Legionnaire's Disease

With New Law Passed, NYC Will Consider Testing Options for Legionnaire's Disease

Aug 19, 2015
|
Madeleine Johnson
Premium

This story has been updated to include comments from the New York City Department of Health and Mental Hygiene

NEW YORK (GenomeWeb) – Amid the largest outbreak of Legionnaire's disease in New York City history, local government here has passed a bill requiring building owners to perform quarterly inspections and testing of so-called cooling towers, the rooftop sites where Legionella bacteria commonly grow.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Herbert Tabor Dies

The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.

Funds to Get Vaccines

The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.

A Number on It

Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.

Nucleic Acids Research Studies on 3D SARS-CoV-2 Structures, Human Brain Atlas, More

In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

Sponsored by
Agena Bioscience

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
20
Featured Webinar

Crystal Digital PCR for Accurate Chimerism Monitoring after Stem Cell Transplantation

Sponsored by
Stilla

This webinar will discuss a new method that relies on Crystal digital PCR from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

What's Popular?

In PCR

  1. Access Genetics Nabs Amended FDA Emergency Use Authorization for Oral Rinse SARS-CoV-2 PCR Test

  2. PerkinElmer Newborn Screening Assay Receives CE-IVD Mark

  3. Fluidigm Finalizes $34M NIH Contract for SARS-CoV-2 Assay Production

  4. BioGX BV Gets CE-IVD Mark for Coronavirus, Flu, RSV Combo Test

  5. Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.